A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Arimoclomol is a small molecule that upregulates "molecular chaperones" in cells under stress. Arimoclomol extends survival by five weeks when given both pre-symptomatically and at disease onset in a mutant superoxide dismutase (SOD1) transgenic mouse model of ALS. Furthermore, it has been demonstrated to have neuroprotective and neuroregenerative effects in other rat models of nerve damage. Molecular chaperone proteins are critical in the cellular response to stress and protein misfolding. Recent data suggest that the SOD1 mutation responsible for ALS in some patients with familial disease reduces the availability of a variety of molecular chaperones, and thus weakens their ability to respond to cellular stress. Protein misfolding and consequent aggregation may play a role in the pathogenesis of both the familial and sporadic forms of ALS. Therapeutic agents such as arimoclomol that improve cellular chaperone response to protein misfolding may be helpful in ALS.
| Condition | Intervention | Phase |
|---|---|---|
|
Amyotrophic Lateral Sclerosis |
Drug: Placebo Drug: Arimoclomol |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With Amyotrophic Lateral Sclerosis (ALS) |
- ALSFRS-R [ Time Frame: 9 months ]
- ALSFRS-R [ Time Frame: 18 months ]
- Survival [ Time Frame: 18 months ]
- Muscle strength [ Time Frame: 9 and 18 months ]
- Pulmonary function [ Time Frame: 9 and 18 months ]
- MUNE [ Time Frame: 9 and 18 months ]
- Quality of Life [ Time Frame: 9 and 18 months ]
| Enrollment: | 0 |
| Arms | Assigned Interventions |
|---|---|
| Placebo Comparator: 1 |
Drug: Placebo
Placebo t.i.d.
|
| Experimental: 2 |
Drug: Arimoclomol
capsule, 400 mg t.i.d.
|
Detailed Description:
This is a Phase 2b double-blind, randomized, placebo-controlled parallel-group study evaluating the safety and efficacy of arimoclomol (400 mg t.i.d.) compared to placebo. A safety lead-in phase will be employed to ensure the safety of all study volunteers.
Tier I (Safety Lead-in): During the enrollment period for the safety lead-in phase, 24 volunteers meeting inclusion/exclusion criteria will be randomized at 4 investigative sites. These volunteers will have weekly visits during the first 4 weeks after starting treatment. Pharmacokinetics (PK) will be performed at various timepoints throughout these 4 weeks. After the initial 4 weeks of treatment, visits will continue at 4-week intervals up to Week 36, subsequently visits will occur every 8 weeks up to Week 68. A final visit will occur at Week 72. There will be a 28-day post study medication Follow-Up Telephone Call to assess medical status and adverse events.
Tier II: After the Tier I volunteers finish 4 weeks of treatment, their data will be reviewed by the IDMC and, if no serious safety issues are identified, the recommendation will be made to start the second enrollment period (Tier II). During Tier II enrollment, volunteers recruited from approximately 30 to 40 centers in the US and Canada will be randomized. After screening and randomization, volunteers will be followed every 4 weeks for 9 months. Subsequently visits will occur every 8 weeks up to Week 68, with interim Follow-Up Telephone Calls at Weeks 16, 24, and 32 and a final visit at Week 72. A Week 76 Follow-Up Telephone Call to assess medical status and adverse events will occur at 28 days post last dose of study medication.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Familial or sporadic ALS.
- Diagnosed with laboratory-supported probable, probable or definite ALS according to the World Federation of Neurology El Escorial criteria for less than or equal to 36 months' duration prior to the Screening Visit.
- Vital capacity (VC) equal to or greater than 70% predicted value for gender, height and age at the Screening Visit.
- Geographic accessibility to the study site.
- Ability to take oral medication at the Screening Visit, based on verbal report.
- Fluency in English, Spanish or Canadian French.
Exclusion Criteria:
- History of known sensitivity or intolerability to arimoclomol or to any other related compound.
- Prior exposure to arimoclomol through a clinical trial or physician-sponsored IND.
- Exposure to any investigational agent within 30 days of the Screening Visit.
Presence of any of the following clinical conditions:
- Substance abuse within the past year
- Unstable cardiac, pulmonary, renal, hepatic, endocrine, hematologic, or active malignancy or infectious disease
- AIDS or AIDS-related complex
- Unstable psychiatric illness defined as psychosis (hallucinations or delusions), untreated major depression within 90 days of the Screening Visit.
- Laboratory values: Screening serum creatinine greater than or equal to 1.5 mg/dL, creatinine clearance less than 70 cc/min, alanine aminotransferase (ALT) greater than 3.0 times the upper limit of normal, total bilirubin greater than 1.5 times the upper limit of normal, white blood cell (WBC) count less than 3,500/mm3, platelet concentration of <100,000/ul, hematocrit level of less than 33 % for female or less than 35 % for male, or coagulation tests (PT, PTT) greater than or equal to 1.5 times upper limit of normal.
- Female volunteers who are breast-feeding.
Contacts and Locations
Hide Study Locations| United States, California | |
| University of California Los Angeles - Tier 2 Site | |
| Pacific Palisades, California, United States, 90272 | |
| University of California - San Francisco - Tier 2 Site | |
| San Francisco, California, United States, 94117 | |
| United States, Colorado | |
| University of Colorado Health Sciences Center - Tier 2 Site | |
| Denver, Colorado, United States, 80262 | |
| United States, Florida | |
| University of Miami - Tier 2 Site | |
| Miami, Florida, United States, 33136 | |
| United States, Georgia | |
| Emory University - Tier 2 site | |
| Atlanta, Georgia, United States, 30322 | |
| United States, Illinois | |
| Northwestern University, Dept. of Neurology - Tier 2 Site | |
| Chicago, Illinois, United States, 60611 | |
| United States, Kansas | |
| University of Kansas Medical Center - Tier 2 site | |
| Kansas City, Kansas, United States, 66160 | |
| United States, Maryland | |
| John Hopkins University - Tier 2 Site | |
| Baltimore, Maryland, United States, 21287 | |
| United States, Massachusetts | |
| Massachusetts General Hospital - Tier 1 Site | |
| Boston, Massachusetts, United States, 02114 | |
| Baystate Medical Center - Tier 2 Site | |
| Springfield, Massachusetts, United States, 01199 | |
| United States, Missouri | |
| Saint Louis University, Neuromuscular Div. - Tier 2 Site | |
| Saint Louis, Missouri, United States, 63110 | |
| Washington University - Tier 2 Site | |
| St. Louis, Missouri, United States, 63110 | |
| United States, Nebraska | |
| BryanLGH Medical Center - Tier 2 Site | |
| Lincoln, Nebraska, United States, 68506 | |
| United States, New York | |
| Upstate Clinical Research, LLC - Tier 2 Site | |
| Albany, New York, United States, 12205 | |
| Mount Sinai School of Medicine - Tier 2 Site | |
| New York, New York, United States, 10029 | |
| Columbia University Medical Center - Tier 2 site | |
| New York, New York, United States, 10032 | |
| SUNY Downstate Medical Center - Tier 1 Site | |
| Syracuse, New York, United States, 13210 | |
| United States, North Carolina | |
| Duke University Medical Center - Tier 1 Site | |
| Durham, North Carolina, United States, 27705 | |
| Wake Forest University School of Medicine -Tier 2 Site | |
| Winston Salem, North Carolina, United States, 27157 | |
| United States, Ohio | |
| Cleveland Clinic Foundation -Tier 2 site | |
| Cleveland, Ohio, United States, 44195 | |
| United States, Oregon | |
| Providence ALS Center - Tier 2 Site | |
| Portland, Oregon, United States, 97213 | |
| United States, Pennsylvania | |
| Pennsylvania State University School of Medicine - Tier 2 Site | |
| Hershey, Pennsylvania, United States, 17033 | |
| Drexel University College of Medicine - Tier 1 Site | |
| Philadelphia, Pennsylvania, United States, 19107 | |
| University of Pittsburgh Medical Center - Tier 2 Site | |
| Pittsburgh, Pennsylvania, United States, 15213 | |
| United States, Tennessee | |
| Vanderbilt University Medical Center - Tier 2 | |
| Nashville, Tennessee, United States, 37232-2551 | |
| United States, Texas | |
| Texas Neurology, PA - Tier 2 Site | |
| Dallas, Texas, United States, 75214 | |
| University of Texas Health Science Center - Tier 2 Site | |
| San Antonio, Texas, United States, 78229-3900 | |
| United States, Vermont | |
| University of Vermont, College of Medicine - Tier 2 | |
| Burlington, Vermont, United States, 05405 | |
| United States, Virginia | |
| University of Virginia - Tier 2 Sites | |
| Charlottesville, Virginia, United States, 22908 | |
| United States, Washington | |
| Virginia Mason Clinic - Tier 2 Site | |
| Seattle, Washington, United States, 98101 | |
| United States, Wisconsin | |
| Medical College of Wisconsin - Tier 2 Site | |
| Milwaukee, Wisconsin, United States, 53226 | |
| Canada, British Columbia | |
| University of British Columbia, Gordon and Leslie Diamond Health Care Centre - Tier 2 Site | |
| Vancouver, British Columbia, Canada, V5Z 2G9 | |
| Canada, Ontario | |
| London Health Science Center - Tier 2 Site | |
| London, Ontario, Canada, N6A 5A5 | |
| University of Toronto, Sunnybrook Health Sciences Centre - Tier 2 Site | |
| Toronto, Ontario, Canada, M4N 3M5 | |
| Canada, Quebec | |
| Montreal Neurological Institute - Tier 2 | |
| Montreal, Quebec, Canada, H3A 2B4 | |
| Principal Investigator: | Merit Cudkowicz, MD, MSc | Massachusetts General Hospital |
| Principal Investigator: | Jeremy Shefner, MD, PhD | State University of New York - Upstate Medical University |
More Information
No publications provided
| Responsible Party: | CytRx |
| ClinicalTrials.gov Identifier: | NCT00561366 History of Changes |
| Other Study ID Numbers: | AALS-003 |
| Study First Received: | November 16, 2007 |
| Last Updated: | February 8, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by CytRx:
|
ALS Lou Gehrig's disease |
Additional relevant MeSH terms:
|
Amyotrophic Lateral Sclerosis Sclerosis Motor Neuron Disease Spinal Cord Diseases Central Nervous System Diseases Nervous System Diseases |
Neurodegenerative Diseases TDP-43 Proteinopathies Neuromuscular Diseases Proteostasis Deficiencies Metabolic Diseases Pathologic Processes |
ClinicalTrials.gov processed this record on May 19, 2013